Spots Global Cancer Trial Database for Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Official Title: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.
Study ID: NCT05387603
Conditions
Study Description
Brief Summary: There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sahlgrenska University Hospital, Dept. of Oncology, Göteborg, , Sweden
Skåne University Hospital, Dept. of Oncology, Lund, , Sweden
Karolinska University Hospital, Dept. of Oncology, Stockholm, , Sweden
Accademical Hospital, Uppsala, Dept. of Oncology, Uppsala, , Sweden
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
